肺癌患者p16基因启动子异常甲基化检测及临床意义  

The detection and clinical diagnostic value of promoter hypermethylation of p16 gene in serum and tissue of lung cancer patients

作　　者：郭秀娟[1] 沈莉[1] 张宏[1] 王珩[1] 

机构地区：[1]河北医科大学第四医院检验科,石家庄市050011

出　　处：《河北医药》2008年第6期757-759,共3页Hebei Medical Journal

基　　金：河北省科技攻关计划项目(编号:072761217)

摘　　要：目的评价组织和血浆中p16基因启动子区甲基化对肺癌的诊断价值。方法用甲基化PCR的方法检测106例肺癌患者组织和血浆p16基因启动子区域甲基化,并评价其对肺癌的诊断价值。结果106例肺癌患者血浆及对应的肿瘤组织中,p16基因甲基化的检出率分别为36.8%(39/106)和41.5%(44/106),二者之间差异无统计学意义(P>0.05)。血浆p16基因启动子异常甲基化阳性率在第2轮PCR扩增后显著增高(P<0.05)。结论血浆标本中p16基因甲基化作为一项肿瘤标志物为早期诊断肺癌提供了依据。Objective To evaluate the diagnostic value of promoter hypermethylation of p16 gene in tissue and plasma specimens in patients with lung cancer. Methods Methylation-specific PCR（MSP）was performed for the detection of promoter hypermethylation of p16 gene in tissue and plasma specimen from 106 lung cancer patients, and the clinical diagnostic value of lung cancer was evaluated . Results The hypermethylation of p16 in promoter regions was detected in 36.8%（39/106） plasma specimens and 41.5% （44/106） corresponding tissue respectively from 106 lung cancer patients. The detectable rate was no significant difference between the plasma specimens and corresponding tissues. The detectable rate of the hypermethylation of p16 in promoter regions was increased in plasma specimen after the second MSP cycle. Conclusion Being a tumor marker, the hypermethylation of p16 gene in promoter regions in plasma specimens could provide evidence for early diagnosis of lung cancer.

关 键 词：肺癌 血浆 组织 P16基因 甲基化 诊断 

分 类 号：R329.28[医药卫生—人体解剖和组织胚胎学] R734.2[医药卫生—基础医学]